title: Methodologic challenges in designing clinical studies to measure differences in the bioequivalence of n-3 fatty acids.
abstract: Although epidemiologic studies suggest a role for alpha-linolenic acid (ALA) in the prevention of coronary heart disease and certain types of cancer, the findings of clinical studies suggest that ALA is inferior biologically to the n-3 long-chain fatty acids because its bioconversion to eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is limited in humans and because the magnitude of its biologic effects is smaller than that of EPA and DHA. This paper reviews several methodologic issues that may confound the findings of clinical studies and complicate our interpretations of them: the ALA and EPA + DHA dietary enrichment levels; the choice of tissue; the choice of lipid species; and the method of reporting fatty acid composition. Although the ALA enrichment levels used in most clinical studies can be achieved by consuming ground flaxseed, flaxseed oil, canola oil and other ALA-rich plants as part of a typical dietary pattern, the EPA + DHA enrichment levels are not practical and can only be obtained from fish oil supplements. The lack of consistency in the choice of lipids species and the reporting of data makes it difficult to compare outcomes across studies. The choice of tissue (blood) for analysis is a limitation that probably cannot be overcome. The use of practical ALA and EPA + DHA dietary enrichment levels and some standardization of clinical study design would allow for greater comparisons of outcomes across studies and ensure a more realistic analysis of how individual n-3 fatty acids differ in their biologic effects in humans.
authors.affiliation: Mainstream Nutrition, Toronto, Ontario, Canada. mainnut@primus.ca
authors.forename: Diane H
authors.initials: DH
authors.lastname: Morris
mesh_terms: D002985:Clinical Protocols; D003327:Coronary Disease / Q000517:prevention & control; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage / Q000493:pharmacokinetics; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D013810:Therapeutic Equivalency
chemical_list: D004042:Dietary Fats, Unsaturated; D015525:Fatty Acids, Omega-3